Effectiveness and tolerance of antituberculosis treatment regimens without isoniazid and rifampicin: Analysis of 85 cases

José R. Tost, Rafael Vidal, José Maldonado, Joan A. Caylà

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To determine if isoniazid- and/or rifampicin-free antituberculosis treatment regimens are safe and effective and to identify any factors that might require changes in the regimens. PATIENTS AND METHODS: We carried out a retrospective study of patients treated with isoniazid- and/or rifampicin-free regimens between 1995 and 2005 at 2 specialized hospitals in Barcelona, Spain. Predictive factors were studied by logistic regression and the odds ratio; 95% confidence intervals were calculated. RESULTS: Eighty-five patients were included in the study: 35% were immigrants and 34% were infected with human immunodeficiency virus. The reason for omitting isoniazid or rifampicin was toxicity (53%), followed by multidrug resistance (39%). Rifampicin-free regimens were most common (42%). A change in the isoniazid- and/or rifampicin-free regimen was required in 30% of cases, but was not associated with being an immigrant. The rate of toxicity with these regimens was higher (36%), although progress was always satisfactory. Clinical course was satisfactory in 77% of patients and they were discharged. CONCLUSIONS: Isoniazid- and/or rifampicin-free regimens with adequate follow-up showed similar treatment outcomes compared with standardized treatment regimens. Although these regimens were more toxic, patient progress was good.

Original languageEnglish (US)
Pages (from-to)478-483
Number of pages6
JournalArchivos de Bronconeumologia
Volume44
Issue number9
DOIs
StatePublished - Sep 1 2008

Keywords

  • Antituberculosis drugs
  • Drug resistance
  • Drug toxicity
  • Mycobacterium tuberculosis
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Effectiveness and tolerance of antituberculosis treatment regimens without isoniazid and rifampicin: Analysis of 85 cases'. Together they form a unique fingerprint.

  • Cite this